|
A study of REOLYSIN in combination with pembrolizumab and chemotherapy in patients (pts) with relapsed metastatic adenocarcinoma of the pancreas (MAP). |
|
|
Consulting or Advisory Role - Amgen; Baxalta; Bayer; EMD Serono |
Speakers' Bureau - Amgen; Bayer; Genentech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Oncolytics |
Travel, Accommodations, Expenses - Oncolytics |
|
|
|
Stock and Other Ownership Interests - Oncolytics |
Travel, Accommodations, Expenses - Oncolytics |
|
|
|
Stock and Other Ownership Interests - Oncolytics |
Travel, Accommodations, Expenses - Oncolytics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |